REFERENCES
Alffenaar, J.-W. C. et al. (2010) ‘Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.’, Clinical pharmacokinetics, 49(8), pp. 559–65. doi: 10.2165/11532080-000000000-00000.
Alliance, G. et al. (2017) ‘Statement on the use of child-friendly fixed-dose combinations for the treatment of TB in children’, WHO, (December 2015), pp. 0–1.
Alsultan, A. and Peloquin, C. A. (2014) ‘Therapeutic drug monitoring in the treatment of tuberculosis: an update.’, Drugs, 74(8), pp. 839–54. doi: 10.1007/s40265-014-0222-8.
Anon (1968) ‘A controlled comparison of thiacetazone (thioacetazone) plus isoniazid with PAS plus isoniazid in Hong Kong.’, Tubercle, 49(3), pp. 243–80. Available at: http://www.ncbi.nlm.nih.gov/pubmed/4179210 (Accessed: 4 September 2013).
Anon (2008a) ‘Amikacin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 87–8. doi: 10.1016/S1472-9792(08)70003-9.
Anon (2008b) ‘Capreomycin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 89–91. doi: 10.1016/S1472-9792(08)70004-0.
Anon (2008c) ‘Clarithromycin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 92–5. doi: 10.1016/S1472-9792(08)70005-2.
Anon (2008d) ‘Clofazimine.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 96–9. doi: 10.1016/S1472-9792(08)70006-4.
Anon (2008e) ‘Cycloserine.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 100–1. doi: 10.1016/S1472-9792(08)70007-6.
Anon (2008f) ‘Ethambutol.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 102–5. doi: 10.1016/S1472-9792(08)70008-8.
Anon (2008g) ‘Isoniazid.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 112–6. doi: 10.1016/S1472-9792(08)70011-8.
Anon (2008h) ‘Levofloxacin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 119–21. doi: 10.1016/S1472-9792(08)70013-1.
Anon (2008i) ‘Linezolid.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 122–5. doi: 10.1016/S1472-9792(08)70014-3.
Anon (2008j) ‘Moxifloxacin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 127–31. doi: 10.1016/S1472-9792(08)70016-7.
Anon (2008k) ‘Para-aminosalicylic acid.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 137–8. doi: 10.1016/S1472-9792(08)70019-2.
Anon (2008l) ‘Prothionamide.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 139–40. doi: 10.1016/S1472-9792(08)70020-9.
Anon (2008m) ‘Pyrazinamide.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 141–4. doi: 10.1016/S1472-9792(08)70021-0.
Anon (2008n) ‘Rifabutin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 145–7. doi: 10.1016/S1472-9792(08)70022-2.
Anon (2008o) ‘Rifampin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 151–4. doi: 10.1016/S1472-9792(08)70024-6.
Anon (2008p) ‘Rifapentine.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 155–8. doi: 10.1016/S1472-9792(08)70025-8.
Anon (2008q) ‘Streptomycin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 162–3. doi: 10.1016/S1472-9792(08)70027-1.
Anon (2008r) ‘TMC-207.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 168–9. doi: 10.1016/S1472-9792(08)70029-5.
Ashley, C and Currie, A. (ed.) (2009) The Renal Drug Handbook. 3rd edn. Radcliffe Medical Press, Oxford.
ASHP (2011) AHFS Drug Information, American Society of Health-System Pharmacists, Bathesda, USA.
Auclair, B. et al. (2001) ‘Pharmacokinetics of Ethionamide Administered under Fasting Conditions or with Orange Juice, Food, or Antacids’, Antimicrobial agents and chemotherapy, 45, pp. 810–4. doi: 10.1128/AAC.45.3.810.
Aventis (2003) ‘Priftin® (rifapentine) tablets prescribing information (dated Feb 2002).’, in Montvale, N. (ed.) Physicians’ desk reference 5th edition. 5th edn. Medical Economics Company Inc, pp. 763–6.
Banerjee, S., Narayanan, M. and Gould, K. (2012) ‘Monitoring aminoglycoside level.’, BMJ (Clinical research ed.), 345, p. e6354. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23044986 (Accessed: 24 August 2013).
Black, H. R., Griffith, R. S. and Peabody, A. M. (1966) ‘Absorption, excretion and metabolism of capreomycin in normal and diseased states.’, Annals of the New York Academy of Sciences, 135(2), pp. 974–82. Available at: http://www.ncbi.nlm.nih.gov/pubmed/5220250 (Accessed: 19 August 2013).
Boeree, M. J. et al. (2015) ‘A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis’, American Journal of Respiratory and Critical Care Medicine, 191(9), pp. 1058–1065. doi: 10.1164/rccm.201407-1264OC.
Boeree, M. J. et al. (2016) ‘High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial’, The Lancet Infectious Diseases. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license, 3099(16), pp. 1–11. doi: 10.1016/S1473-3099(16)30274-2.
Bolhuis, M. S. et al. (2010) ‘Clarithromycin significantly increases linezolid serum concentrations.’, Antimicrobial agents and chemotherapy, 54(12), pp. 5418–9. doi: 10.1128/AAC.00757-10.
Bolhuis, M. S. et al. (2013) ‘Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients.’, The European respiratory journal, 42(6), pp. 1614–21. doi: 10.1183/09031936.00001913.
British National Formulary (2013). The British Medical Association and the Royal Pharmaceutical Society. Available at: www.bnf.org.
British National Formulary For Children (2013). British Medical Association, Royal Pharmaceutical Society, Royal College of Paediatrics and Child Health, and Neonatal and Paediatric Pharmacists Group. Available at: www.bnfc.org.
Cabrera-rivero, J. L. et al. (2012) ‘new england journal’, pp. 2151–2160.
Caminero, J. A. (2013) ‘Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis 2013’, International Union Against Tuberculosis And Lung Disease. International Union Against Tuberculosis And Lung Disease.
Chambers, H. F. et al. (2005) ‘Imipenem for treatment of tuberculosis in mice and humans.’, Antimicrobial agents and chemotherapy, 49(7), pp. 2816–21. doi: 10.1128/AAC.49.7.2816-2821.2005.
Chan, S. L. et al. (1994) ‘Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals’, International Journal of Antimicrobial Agents, 3(4), pp. 267–274. doi: 10.1016/0924-8579(94)90054-X.
Chaulet, P., Raviglione, M. and Bustreo, F. (1996) ‘Epidemiology, control and treatment of multidrug-resistant tuberculosis.’, Drugs, 52 Suppl 2, pp. 103–7; discussion 107-8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8869846 (Accessed: 19 August 2013).
Choudhri, S. H. et al. (1995) ‘Clofazimine induced cardiotoxicity--a case report.’, Leprosy review, 66(1), pp. 63–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7731343 (Accessed: 6 November 2013).
Conradie, F. et al. (2022) ‘Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis’, New England Journal of Medicine. Massachusetts Medical Society, 387(9), pp. 810–823. doi: 10.1056/NEJMoa2119430.
Court, R. et al. (2018) ‘Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis’, The International Journal of Tuberculosis and Lung Disease, 22(1), pp. 30–33. doi: 10.5588/ijtld.17.0475.
Cox, H. and Ford, N. (2012) ‘Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 16(4), pp. 447–54. doi: 10.5588/ijtld.11.0451.
Curry International Tuberculosis Center (2022) Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 3rd edn.
Dannemann, B. et al. (2012) ‘QTcF prolongation in a Phase II trial of TMC207 plus background regimen as treatment for multidrug-resistant tuberculosis: effect of co-administration with clofazimine’, 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy.
Dauby, N. et al. (2011) ‘Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis.’, The Pediatric infectious disease journal, 30(9), pp. 812–3. doi: 10.1097/INF.0b013e3182154b05.
Devine, B. (1974) ‘Gentamicin therapy’, Drug Intell Clin Pharm, 8, pp. 650–655.
Dey, T. et al. (2013) ‘Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.’, The Journal of antimicrobial chemotherapy, 68(2), pp. 284–93. doi: 10.1093/jac/dks389.
Diacon, A. H. et al. (2009) ‘The diarylquinoline TMC207 for multidrug-resistant tuberculosis.’, The New England journal of medicine, 360(23), pp. 2397–405. doi: 10.1056/NEJMoa0808427.
Diacon, Andreas H et al. (2012) ‘14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.’, Lancet, 380(9846), pp. 986–93. doi: 10.1016/S0140-6736(12)61080-0.
Diacon, A H et al. (2012) ‘Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.’, Antimicrobial agents and chemotherapy, 56(6), pp. 3271–6. doi: 10.1128/AAC.06126-11.
Diacon, A. H. et al. (2014) ‘Multidrug-resistant tuberculosis and culture conversion with bedaquiline.’, The New England journal of medicine, 371(8), pp. 723–32. doi: 10.1056/NEJMoa1313865.
Donald, P. R. et al. (2001) ‘Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis.’, Scandinavian journal of infectious diseases, 33(6), pp. 466–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11450868 (Accessed: 24 August 2013).
Durrant JD, Campbell K, F. S. et al (2009) Ototoxicity Monitoring, American Academy of Audiology. Available at: http://www.audiology.org/resources/documentlibrary/Documents/OtoMonGuidelines.pdf.
Dutta, B. S. et al. (2012) ‘Ethionamide-induced hypothyroidism.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 16(1), p. 141. doi: 10.5588/ijtld.11.0388.
Falzon, D. et al. (2011) ‘WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.’, The European respiratory journal, 38(3), pp. 516–28. doi: 10.1183/09031936.00073611.
Garcia-Prats, AJ Donald, PR Hesseling, AC Schaaf, H. (2013) ‘Second-Line Antituberculosis Drugs in Children: A Commissioned Review for the World Health Organization 19th Expert Committee on the Selection and Use of Essential Medicines’, World Health Organisation. Available at: www.who.int/selection_medicines/committees/expert/19/applications/TB_624_C_R.pdf.
Goh, T. L. et al. (2011) ‘Extensively drug-resistant tuberculosis: New Zealand’s first case and the challenges of management in a low-prevalence country.’, The Medical journal of Australia, 194(11), pp. 602–4. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21644877 (Accessed: 24 August 2013).
Gonzalo, X. and Drobniewski, F. (2013) ‘Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.’, The Journal of antimicrobial chemotherapy, 68(2), pp. 366–9. doi: 10.1093/jac/dks395.
Gordin, F. et al. (2011) ‘new england journal’, pp. 2155–2166.
Gynaecology, R. C. of O. and (2011) Drug Interactions with Hormonal Contraception. Faculty of Sexual & Reproductive Healthcare Clinical Guidance. Available at: http://www.fsrh.org/pdfs/CEUguidancedruginteractionshormonal.pdf.
Hasenbosch, R. E. et al. (2008) ‘Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 12(8), pp. 967–71. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18647459 (Accessed: 21 February 2017).
Hoc, A. et al. (1994) ‘Audiologic Management of Individuals Receiving Cochleotoxic Drug Therapy’. doi: 10.1044/policy.GL1994-00003.
Hutchison TA, S. D. & A. M. (no date) Drugdex System Internet version Micromedex Inc. Greenwood Village, Colorado.
Im, J. H. et al. (2015) ‘Incidence and risk factors of linezolid-induced lactic acidosis’, International Journal of Infectious Diseases, 31, pp. 47–52. doi: 10.1016/j.ijid.2014.12.009.
Janssen (2012a) ‘Anti-Infective Drugs Advisory Committee Meeting Briefing Document: TMC207 (bedaquiline): Treatment of Patients with MDR-TB’, NDA, pp. 204–384.
Janssen (2012b) ‘Compassionate Use Program of TMC207 in Patients with Extensively Drug Resistant (XDR) or Pre-XDR Mycobacterium tuberculosis (MTB) Pulmonary Infection’, Guidelines for physicians and pharmacists.
Janssen (2012c) SirturoTM U.S. Food and Drug Administration bedaquiline package insert. Available at: http://www.who.int/tb/challenges/mdr/bedaquiline/en/index.html.
Jindani, A. et al. (2014) ‘High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis’, New England Journal of Medicine, 371(17), pp. 1599–1608. doi: 10.1056/NEJMoa1314210.
Katiyar, S. K. et al. (2008) ‘A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 12(2), pp. 139–45. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18230245 (Accessed: 4 September 2013).
Lee, M. et al. (2012) ‘Linezolid for treatment of chronic extensively drug-resistant tuberculosis.’, The New England journal of medicine, 367(16), pp. 1508–18. doi: 10.1056/NEJMoa1201964.
Lee, M. et al. (2015) ‘Linezolid for XDR-TB — Final Study Outcomes’, New England Journal of Medicine, 373(3), pp. 290–291. doi: 10.1056/NEJMc1500286.
Lehmann, C. R. et al. (1988) ‘Capreomycin kinetics in renal impairment and clearance by hemodialysis.’, The American review of respiratory disease, 138(5), pp. 1312–3. doi: 10.1164/ajrccm/138.5.1312.
Loeffler, A. et al (2011) Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 2nd edn. Curry International Tuberculosis Center and California Department of Public Health.
De Lorenzo, S. et al. (2013) ‘Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.’, The European respiratory journal, 41(6), pp. 1386–92. doi: 10.1183/09031936.00124312.
Migliori, G. B. et al. (2009) ‘A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.’, The European respiratory journal, 34(2), pp. 387–93. doi: 10.1183/09031936.00009509.
Milburn, H. et al. (2010) ‘Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease.’, Thorax, 65(6), pp. 557–70. doi: 10.1136/thx.2009.133173.
Mulubwa, M. and Mugabo, P. (2019) ‘Amount of Cycloserine Emanating from Terizidone Metabolism and Relationship with Hepatic Function in Patients with Drug-Resistant Tuberculosis’, Drugs in R&D, 19(3), pp. 289–296. doi: 10.1007/s40268-019-00281-4.
Mylan IRE Healthcare Limited (2022) Summary of Product Characteristics: Dovprela®., Electronic Medicines Compendium: Datapharm Communications Ltd. Available at: http://emc.medicines.org.uk.
National Collaborating Centre for Chronic Conditions (UK); Centre for Clinical Practice at NICE (UK (2011) Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control.
Nyang’wa, B.-T. et al. (2022) ‘A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis’, New England Journal of Medicine. Massachusetts Medical Society, 387(25), pp. 2331–2343. doi: 10.1056/NEJMoa2117166.
Organisation, W. H. (2012) ‘Interim guidance on the use of bedaquiline to treat MDR-TB’, World Health Organisation, p. WHO/HTM/TB/2013.6.
Payen, M. C. et al. (2012) ‘Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 16(4), pp. 558–60. doi: 10.5588/ijtld.11.0414.
Peloquin, C. A. (1993) ‘Pharmacology of the antimycobacterial drugs.’, The Medical clinics of North America, 77(6), pp. 1253–62. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8231410 (Accessed: 19 August 2013).
Peloquin, C. A. et al. (1999) ‘Once-daily and twice-daily dosing of p-aminosalicylic acid granules.’, American journal of respiratory and critical care medicine, 159(3), pp. 932–4. doi: 10.1164/ajrccm.159.3.9807131.
Peloquin, C. A. (2002) ‘Therapeutic drug monitoring in the treatment of tuberculosis.’, Drugs, 62(15), pp. 2169–83. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12381217 (Accessed: 4 September 2013).
Peloquin, C. A. et al. (2004) ‘Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases.’, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 38(11), pp. 1538–44. doi: 10.1086/420742.
PfizerTrecator® (2007) U.S. Physician Prescribing Information, PfizerTrecator®. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=473 (Accessed: 28 August 2013).
Pharmaceuticals, K. (no date) ‘Personal communication: Capreomycin and intravenous administration.’
Pranger, A. D. et al. (2011) ‘Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience.’, The European respiratory journal, 38(4), pp. 888–94. doi: 10.1183/09031936.00176610.
Prasad, R. et al. (no date) ‘Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.’, The Indian journal of chest diseases & allied sciences, 48(3), pp. 183–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18610675 (Accessed: 24 August 2013).
Rose, P. C. et al. (2012) ‘Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 16(12), pp. 1588–93. doi: 10.5588/ijtld.12.0322.
Ruslami, R. et al. (2013) ‘Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.’, The Lancet infectious diseases, 13(1), pp. 27–35. doi: 10.1016/S1473-3099(12)70264-5.
Rustomjee, R. et al. (2008) ‘Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis.’, Antimicrobial agents and chemotherapy, 52(8), pp. 2831–5. doi: 10.1128/AAC.01204-07.
Schaaf, H. S. and Marais, B. J. (2011) ‘Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians.’, Paediatric respiratory reviews, 12(1), pp. 31–8. doi: 10.1016/j.prrv.2010.09.010.
Schilling, R. (2013) ‘Appropriate monitoring for prolonged QT’, Unpublished communication.
Seddon, J. a et al. (2012) ‘Caring for children with drug-resistant tuberculosis: practice-based recommendations.’, American journal of respiratory and critical care medicine, 186(10), pp. 953–64. doi: 10.1164/rccm.201206-1001CI.
Skripconoka, V. et al. (2013) ‘Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.’, The European respiratory journal, 41(6), pp. 1393–400. doi: 10.1183/09031936.00125812.
Sotgiu, G. et al. (2012) ‘Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.’, The European respiratory journal, 40(6), pp. 1430–42. doi: 10.1183/09031936.00022912.
Sotgiu, G. et al. (2016) ‘Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review’, International Journal of Molecular Sciences, 17(3), p. 373. doi: 10.3390/ijms17030373.
Soumakis, S. A., Berg, D. and Harris, H. W. (1998) ‘Hypothyroidism in a Patient Receiving Treatment for Multidrug‐Resistant Tuberculosis’, Clinical Infectious Diseases, 27(4), pp. 910–911. doi: 10.1086/517171.
Srivastava, S. et al. (2013) ‘Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?’, The European respiratory journal, 42(6), pp. 1449–53. doi: 10.1183/09031936.00073213.
STOP TB Partnership, Child Health Subgroup, World Health Organisation, Geneva, S. (2010) ‘Rapid advice: Treatment of Tuberculosis in Children’, WHO, p. WHO/HTM/TB/2010.13.
STOP TB Partnership Child Health Subgroup, W. H. O. (2006) ‘Guidance for national tuberculosis programmes on the management of tuberculosis in children. Chapter 2: anti-tuberculosis treatment in children.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 10(11), pp. 1205–11. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17131777 (Accessed: 4 September 2013).
Sturdy, A. et al. (2011) ‘Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.’, The Journal of antimicrobial chemotherapy, 66(8), pp. 1815–20. doi: 10.1093/jac/dkr221.
Sweetman S, M. (ed.) (no date) The Complete Drug Reference, online edition., The Pharmaceutical Press, London. The Pharmaceutical Press, London.
Tang, S. et al. (2015) ‘Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.’, The European respiratory journal, 45(1), pp. 161–70. doi: 10.1183/09031936.00035114.
The Sentinel Project for Pediatric Drug-Resistant Tuberculosis (2015) ‘Management of Multidrug-Resistant Tuberculosis in Children: A Field Guide’, (March). Available at: http://sentinel-project.org/wp-content/uploads/2015/03/Field_Handbook_2nd_Ed_revised-no-logos_03022015.pdf.
Thee, S., Zöllner, E. W., et al. (2011) ‘Abnormal thyroid function tests in children on ethionamide treatment.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 15(9), pp. 1191–3, i. doi: 10.5588/ijtld.10.0707.
Thee, S., Seifart, H. I., et al. (2011) ‘Pharmacokinetics of ethionamide in children.’, Antimicrobial agents and chemotherapy, 55(10), pp. 4594–600. doi: 10.1128/AAC.00379-11.
Tiberi, S. et al. (2016) ‘Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience: TABLE 1’, European Respiratory Journal, 47(1), pp. 333–336. doi: 10.1183/13993003.01278-2015.
Treatment of Tuberculosis: Thioacetazone (no date) People’s Friendship University of Russia, Faculty of Medicine. Available at: http://main.rudn.ru/_new/russian/win/tub1/tubeng2012/05_treat/05_1_7_treat_tiacet.htm.
Tucker, H. (2005) Dear Healthcare Professional Letter. Available at: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM164879.pdf.
WHO (2004) Statement on the position of the stop TB department with regard to thioacetazone + isoniazid within context of the who model list of essential medicines., World Health Organisation. Available at: http://archives.who.int/eml/expcom/expcom14/thioacetazone/thioacetazoneisoniazid_STB_statement_annex_4Nov04.pdf.
WHO (2006) ‘Guidance for National Tuberculosis Programmes on the management of tuberculosis in children’, World Health Organisation. Geneva, p. WHO/HTM/ TB/2006.371, WHO/FCH/CAH/2006.7.
WHO (2009) ‘Treatment of Tuberculosis: guidelines 4th edition.’, WHO, p. WHO/HTM/TB/2009.4.
WHO (2011) ‘Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 Update’, World Health Organisation, p. WHO/HTM/TB/2008.402.
WHO (2013) ‘The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance.’, Geneva: World Health Organization. Available at: http://www.ncbi.nlm.nih.gov/books/NBK154134/.
WHO (2014a) Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis., World Health Organisation. Geneva, Switzerland: World Health Organisation. Available at: http://www.who.int/tb/publications/pmdt_companionhandbook/en/.
WHO (2014b) ‘The use of delamanid in the treatment of multidrug-resistant tuberculosis: An interim policy guidance.’, World Health Organisation. Geneva, Switzerland, (WHO/HTM/TB/2014.23). Available at: http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf?ua=1&ua=1.
WHO (2015) Guidelines on the management of latent tuberculosis infection. Geneva, Switzerland. Available at: http://apps.who.int/iris/bitstream/10665/136471/1/9789241548908_eng.pdf?ua=1&ua=1.
WHO (2022a) ‘Use of delamanid in children and adolescents with multidrug-and rifampicin-resistant tuberculosis-Information note WHO recommendations for delamanid in children and adolescents’, 4(6), pp. 1–8.
WHO (2022b) WHO consolidated guidelines on tuberculosis., WHO Press.
World Health Organization (2018) ‘Technical report on the pharmacokinetics and pharmacodynamics (PK/PD) of medicines used in the treatment of drug-resistant tuberculosis.’, p. 63. Available at: http://apps.who.int/bookorders. (Accessed: 26 April 2020).
World Health Organization (2023) ‘Use of bedaquiline in children and adolescents with multidrug-and rifampicin-resistant tuberculosis-Information note BEDAQUILINE’, 4(5), pp. 1–8. Available at: https://www.who.int/publications/i/item/9789240074286.
Xu, H.-B., Jiang, R.-H. and Xiao, H.-P. (2012) ‘Clofazimine in the treatment of multidrug-resistant tuberculosis.’, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 18(11), pp. 1104–10. doi: 10.1111/j.1469-0691.2011.03716.x.
Zhang, X. et al. (2015) ‘Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.’, Journal of thoracic disease, 7(4), pp. 603–15. doi: 10.3978/j.issn.2072-1439.2015.03.10.
Zhu, M. et al. (2001) ‘Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis.’, Pharmacotherapy, 21(9), pp. 1037–45. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11560193 (Accessed: 4 September 2013).
Zhu, M. et al. (2002) ‘Population pharmacokinetics of ethionamide in patients with tuberculosis.’, Tuberculosis (Edinburgh, Scotland), 82(2–3), pp. 91–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12356460 (Accessed: 26 April 2014).
Alffenaar, J.-W. C. et al. (2010) ‘Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.’, Clinical pharmacokinetics, 49(8), pp. 559–65. doi: 10.2165/11532080-000000000-00000.
Alliance, G. et al. (2017) ‘Statement on the use of child-friendly fixed-dose combinations for the treatment of TB in children’, WHO, (December 2015), pp. 0–1.
Alsultan, A. and Peloquin, C. A. (2014) ‘Therapeutic drug monitoring in the treatment of tuberculosis: an update.’, Drugs, 74(8), pp. 839–54. doi: 10.1007/s40265-014-0222-8.
Anon (1968) ‘A controlled comparison of thiacetazone (thioacetazone) plus isoniazid with PAS plus isoniazid in Hong Kong.’, Tubercle, 49(3), pp. 243–80. Available at: http://www.ncbi.nlm.nih.gov/pubmed/4179210 (Accessed: 4 September 2013).
Anon (2008a) ‘Amikacin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 87–8. doi: 10.1016/S1472-9792(08)70003-9.
Anon (2008b) ‘Capreomycin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 89–91. doi: 10.1016/S1472-9792(08)70004-0.
Anon (2008c) ‘Clarithromycin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 92–5. doi: 10.1016/S1472-9792(08)70005-2.
Anon (2008d) ‘Clofazimine.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 96–9. doi: 10.1016/S1472-9792(08)70006-4.
Anon (2008e) ‘Cycloserine.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 100–1. doi: 10.1016/S1472-9792(08)70007-6.
Anon (2008f) ‘Ethambutol.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 102–5. doi: 10.1016/S1472-9792(08)70008-8.
Anon (2008g) ‘Isoniazid.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 112–6. doi: 10.1016/S1472-9792(08)70011-8.
Anon (2008h) ‘Levofloxacin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 119–21. doi: 10.1016/S1472-9792(08)70013-1.
Anon (2008i) ‘Linezolid.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 122–5. doi: 10.1016/S1472-9792(08)70014-3.
Anon (2008j) ‘Moxifloxacin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 127–31. doi: 10.1016/S1472-9792(08)70016-7.
Anon (2008k) ‘Para-aminosalicylic acid.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 137–8. doi: 10.1016/S1472-9792(08)70019-2.
Anon (2008l) ‘Prothionamide.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 139–40. doi: 10.1016/S1472-9792(08)70020-9.
Anon (2008m) ‘Pyrazinamide.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 141–4. doi: 10.1016/S1472-9792(08)70021-0.
Anon (2008n) ‘Rifabutin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 145–7. doi: 10.1016/S1472-9792(08)70022-2.
Anon (2008o) ‘Rifampin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 151–4. doi: 10.1016/S1472-9792(08)70024-6.
Anon (2008p) ‘Rifapentine.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 155–8. doi: 10.1016/S1472-9792(08)70025-8.
Anon (2008q) ‘Streptomycin.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 162–3. doi: 10.1016/S1472-9792(08)70027-1.
Anon (2008r) ‘TMC-207.’, Tuberculosis (Edinburgh, Scotland), 88(2), pp. 168–9. doi: 10.1016/S1472-9792(08)70029-5.
Ashley, C and Currie, A. (ed.) (2009) The Renal Drug Handbook. 3rd edn. Radcliffe Medical Press, Oxford.
ASHP (2011) AHFS Drug Information, American Society of Health-System Pharmacists, Bathesda, USA.
Auclair, B. et al. (2001) ‘Pharmacokinetics of Ethionamide Administered under Fasting Conditions or with Orange Juice, Food, or Antacids’, Antimicrobial agents and chemotherapy, 45, pp. 810–4. doi: 10.1128/AAC.45.3.810.
Aventis (2003) ‘Priftin® (rifapentine) tablets prescribing information (dated Feb 2002).’, in Montvale, N. (ed.) Physicians’ desk reference 5th edition. 5th edn. Medical Economics Company Inc, pp. 763–6.
Banerjee, S., Narayanan, M. and Gould, K. (2012) ‘Monitoring aminoglycoside level.’, BMJ (Clinical research ed.), 345, p. e6354. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23044986 (Accessed: 24 August 2013).
Black, H. R., Griffith, R. S. and Peabody, A. M. (1966) ‘Absorption, excretion and metabolism of capreomycin in normal and diseased states.’, Annals of the New York Academy of Sciences, 135(2), pp. 974–82. Available at: http://www.ncbi.nlm.nih.gov/pubmed/5220250 (Accessed: 19 August 2013).
Boeree, M. J. et al. (2015) ‘A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis’, American Journal of Respiratory and Critical Care Medicine, 191(9), pp. 1058–1065. doi: 10.1164/rccm.201407-1264OC.
Boeree, M. J. et al. (2016) ‘High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial’, The Lancet Infectious Diseases. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license, 3099(16), pp. 1–11. doi: 10.1016/S1473-3099(16)30274-2.
Bolhuis, M. S. et al. (2010) ‘Clarithromycin significantly increases linezolid serum concentrations.’, Antimicrobial agents and chemotherapy, 54(12), pp. 5418–9. doi: 10.1128/AAC.00757-10.
Bolhuis, M. S. et al. (2013) ‘Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients.’, The European respiratory journal, 42(6), pp. 1614–21. doi: 10.1183/09031936.00001913.
British National Formulary (2013). The British Medical Association and the Royal Pharmaceutical Society. Available at: www.bnf.org.
British National Formulary For Children (2013). British Medical Association, Royal Pharmaceutical Society, Royal College of Paediatrics and Child Health, and Neonatal and Paediatric Pharmacists Group. Available at: www.bnfc.org.
Cabrera-rivero, J. L. et al. (2012) ‘new england journal’, pp. 2151–2160.
Caminero, J. A. (2013) ‘Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis 2013’, International Union Against Tuberculosis And Lung Disease. International Union Against Tuberculosis And Lung Disease.
Chambers, H. F. et al. (2005) ‘Imipenem for treatment of tuberculosis in mice and humans.’, Antimicrobial agents and chemotherapy, 49(7), pp. 2816–21. doi: 10.1128/AAC.49.7.2816-2821.2005.
Chan, S. L. et al. (1994) ‘Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals’, International Journal of Antimicrobial Agents, 3(4), pp. 267–274. doi: 10.1016/0924-8579(94)90054-X.
Chaulet, P., Raviglione, M. and Bustreo, F. (1996) ‘Epidemiology, control and treatment of multidrug-resistant tuberculosis.’, Drugs, 52 Suppl 2, pp. 103–7; discussion 107-8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8869846 (Accessed: 19 August 2013).
Choudhri, S. H. et al. (1995) ‘Clofazimine induced cardiotoxicity--a case report.’, Leprosy review, 66(1), pp. 63–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7731343 (Accessed: 6 November 2013).
Conradie, F. et al. (2022) ‘Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis’, New England Journal of Medicine. Massachusetts Medical Society, 387(9), pp. 810–823. doi: 10.1056/NEJMoa2119430.
Court, R. et al. (2018) ‘Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis’, The International Journal of Tuberculosis and Lung Disease, 22(1), pp. 30–33. doi: 10.5588/ijtld.17.0475.
Cox, H. and Ford, N. (2012) ‘Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 16(4), pp. 447–54. doi: 10.5588/ijtld.11.0451.
Curry International Tuberculosis Center (2022) Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 3rd edn.
Dannemann, B. et al. (2012) ‘QTcF prolongation in a Phase II trial of TMC207 plus background regimen as treatment for multidrug-resistant tuberculosis: effect of co-administration with clofazimine’, 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy.
Dauby, N. et al. (2011) ‘Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis.’, The Pediatric infectious disease journal, 30(9), pp. 812–3. doi: 10.1097/INF.0b013e3182154b05.
Devine, B. (1974) ‘Gentamicin therapy’, Drug Intell Clin Pharm, 8, pp. 650–655.
Dey, T. et al. (2013) ‘Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.’, The Journal of antimicrobial chemotherapy, 68(2), pp. 284–93. doi: 10.1093/jac/dks389.
Diacon, A. H. et al. (2009) ‘The diarylquinoline TMC207 for multidrug-resistant tuberculosis.’, The New England journal of medicine, 360(23), pp. 2397–405. doi: 10.1056/NEJMoa0808427.
Diacon, Andreas H et al. (2012) ‘14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.’, Lancet, 380(9846), pp. 986–93. doi: 10.1016/S0140-6736(12)61080-0.
Diacon, A H et al. (2012) ‘Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.’, Antimicrobial agents and chemotherapy, 56(6), pp. 3271–6. doi: 10.1128/AAC.06126-11.
Diacon, A. H. et al. (2014) ‘Multidrug-resistant tuberculosis and culture conversion with bedaquiline.’, The New England journal of medicine, 371(8), pp. 723–32. doi: 10.1056/NEJMoa1313865.
Donald, P. R. et al. (2001) ‘Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis.’, Scandinavian journal of infectious diseases, 33(6), pp. 466–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11450868 (Accessed: 24 August 2013).
Durrant JD, Campbell K, F. S. et al (2009) Ototoxicity Monitoring, American Academy of Audiology. Available at: http://www.audiology.org/resources/documentlibrary/Documents/OtoMonGuidelines.pdf.
Dutta, B. S. et al. (2012) ‘Ethionamide-induced hypothyroidism.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 16(1), p. 141. doi: 10.5588/ijtld.11.0388.
Falzon, D. et al. (2011) ‘WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.’, The European respiratory journal, 38(3), pp. 516–28. doi: 10.1183/09031936.00073611.
Garcia-Prats, AJ Donald, PR Hesseling, AC Schaaf, H. (2013) ‘Second-Line Antituberculosis Drugs in Children: A Commissioned Review for the World Health Organization 19th Expert Committee on the Selection and Use of Essential Medicines’, World Health Organisation. Available at: www.who.int/selection_medicines/committees/expert/19/applications/TB_624_C_R.pdf.
Goh, T. L. et al. (2011) ‘Extensively drug-resistant tuberculosis: New Zealand’s first case and the challenges of management in a low-prevalence country.’, The Medical journal of Australia, 194(11), pp. 602–4. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21644877 (Accessed: 24 August 2013).
Gonzalo, X. and Drobniewski, F. (2013) ‘Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.’, The Journal of antimicrobial chemotherapy, 68(2), pp. 366–9. doi: 10.1093/jac/dks395.
Gordin, F. et al. (2011) ‘new england journal’, pp. 2155–2166.
Gynaecology, R. C. of O. and (2011) Drug Interactions with Hormonal Contraception. Faculty of Sexual & Reproductive Healthcare Clinical Guidance. Available at: http://www.fsrh.org/pdfs/CEUguidancedruginteractionshormonal.pdf.
Hasenbosch, R. E. et al. (2008) ‘Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 12(8), pp. 967–71. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18647459 (Accessed: 21 February 2017).
Hoc, A. et al. (1994) ‘Audiologic Management of Individuals Receiving Cochleotoxic Drug Therapy’. doi: 10.1044/policy.GL1994-00003.
Hutchison TA, S. D. & A. M. (no date) Drugdex System Internet version Micromedex Inc. Greenwood Village, Colorado.
Im, J. H. et al. (2015) ‘Incidence and risk factors of linezolid-induced lactic acidosis’, International Journal of Infectious Diseases, 31, pp. 47–52. doi: 10.1016/j.ijid.2014.12.009.
Janssen (2012a) ‘Anti-Infective Drugs Advisory Committee Meeting Briefing Document: TMC207 (bedaquiline): Treatment of Patients with MDR-TB’, NDA, pp. 204–384.
Janssen (2012b) ‘Compassionate Use Program of TMC207 in Patients with Extensively Drug Resistant (XDR) or Pre-XDR Mycobacterium tuberculosis (MTB) Pulmonary Infection’, Guidelines for physicians and pharmacists.
Janssen (2012c) SirturoTM U.S. Food and Drug Administration bedaquiline package insert. Available at: http://www.who.int/tb/challenges/mdr/bedaquiline/en/index.html.
Jindani, A. et al. (2014) ‘High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis’, New England Journal of Medicine, 371(17), pp. 1599–1608. doi: 10.1056/NEJMoa1314210.
Katiyar, S. K. et al. (2008) ‘A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 12(2), pp. 139–45. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18230245 (Accessed: 4 September 2013).
Lee, M. et al. (2012) ‘Linezolid for treatment of chronic extensively drug-resistant tuberculosis.’, The New England journal of medicine, 367(16), pp. 1508–18. doi: 10.1056/NEJMoa1201964.
Lee, M. et al. (2015) ‘Linezolid for XDR-TB — Final Study Outcomes’, New England Journal of Medicine, 373(3), pp. 290–291. doi: 10.1056/NEJMc1500286.
Lehmann, C. R. et al. (1988) ‘Capreomycin kinetics in renal impairment and clearance by hemodialysis.’, The American review of respiratory disease, 138(5), pp. 1312–3. doi: 10.1164/ajrccm/138.5.1312.
Loeffler, A. et al (2011) Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 2nd edn. Curry International Tuberculosis Center and California Department of Public Health.
De Lorenzo, S. et al. (2013) ‘Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.’, The European respiratory journal, 41(6), pp. 1386–92. doi: 10.1183/09031936.00124312.
Migliori, G. B. et al. (2009) ‘A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.’, The European respiratory journal, 34(2), pp. 387–93. doi: 10.1183/09031936.00009509.
Milburn, H. et al. (2010) ‘Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease.’, Thorax, 65(6), pp. 557–70. doi: 10.1136/thx.2009.133173.
Mulubwa, M. and Mugabo, P. (2019) ‘Amount of Cycloserine Emanating from Terizidone Metabolism and Relationship with Hepatic Function in Patients with Drug-Resistant Tuberculosis’, Drugs in R&D, 19(3), pp. 289–296. doi: 10.1007/s40268-019-00281-4.
Mylan IRE Healthcare Limited (2022) Summary of Product Characteristics: Dovprela®., Electronic Medicines Compendium: Datapharm Communications Ltd. Available at: http://emc.medicines.org.uk.
National Collaborating Centre for Chronic Conditions (UK); Centre for Clinical Practice at NICE (UK (2011) Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control.
Nyang’wa, B.-T. et al. (2022) ‘A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis’, New England Journal of Medicine. Massachusetts Medical Society, 387(25), pp. 2331–2343. doi: 10.1056/NEJMoa2117166.
Organisation, W. H. (2012) ‘Interim guidance on the use of bedaquiline to treat MDR-TB’, World Health Organisation, p. WHO/HTM/TB/2013.6.
Payen, M. C. et al. (2012) ‘Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 16(4), pp. 558–60. doi: 10.5588/ijtld.11.0414.
Peloquin, C. A. (1993) ‘Pharmacology of the antimycobacterial drugs.’, The Medical clinics of North America, 77(6), pp. 1253–62. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8231410 (Accessed: 19 August 2013).
Peloquin, C. A. et al. (1999) ‘Once-daily and twice-daily dosing of p-aminosalicylic acid granules.’, American journal of respiratory and critical care medicine, 159(3), pp. 932–4. doi: 10.1164/ajrccm.159.3.9807131.
Peloquin, C. A. (2002) ‘Therapeutic drug monitoring in the treatment of tuberculosis.’, Drugs, 62(15), pp. 2169–83. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12381217 (Accessed: 4 September 2013).
Peloquin, C. A. et al. (2004) ‘Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases.’, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 38(11), pp. 1538–44. doi: 10.1086/420742.
PfizerTrecator® (2007) U.S. Physician Prescribing Information, PfizerTrecator®. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=473 (Accessed: 28 August 2013).
Pharmaceuticals, K. (no date) ‘Personal communication: Capreomycin and intravenous administration.’
Pranger, A. D. et al. (2011) ‘Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience.’, The European respiratory journal, 38(4), pp. 888–94. doi: 10.1183/09031936.00176610.
Prasad, R. et al. (no date) ‘Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.’, The Indian journal of chest diseases & allied sciences, 48(3), pp. 183–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18610675 (Accessed: 24 August 2013).
Rose, P. C. et al. (2012) ‘Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 16(12), pp. 1588–93. doi: 10.5588/ijtld.12.0322.
Ruslami, R. et al. (2013) ‘Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.’, The Lancet infectious diseases, 13(1), pp. 27–35. doi: 10.1016/S1473-3099(12)70264-5.
Rustomjee, R. et al. (2008) ‘Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis.’, Antimicrobial agents and chemotherapy, 52(8), pp. 2831–5. doi: 10.1128/AAC.01204-07.
Schaaf, H. S. and Marais, B. J. (2011) ‘Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians.’, Paediatric respiratory reviews, 12(1), pp. 31–8. doi: 10.1016/j.prrv.2010.09.010.
Schilling, R. (2013) ‘Appropriate monitoring for prolonged QT’, Unpublished communication.
Seddon, J. a et al. (2012) ‘Caring for children with drug-resistant tuberculosis: practice-based recommendations.’, American journal of respiratory and critical care medicine, 186(10), pp. 953–64. doi: 10.1164/rccm.201206-1001CI.
Skripconoka, V. et al. (2013) ‘Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.’, The European respiratory journal, 41(6), pp. 1393–400. doi: 10.1183/09031936.00125812.
Sotgiu, G. et al. (2012) ‘Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.’, The European respiratory journal, 40(6), pp. 1430–42. doi: 10.1183/09031936.00022912.
Sotgiu, G. et al. (2016) ‘Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review’, International Journal of Molecular Sciences, 17(3), p. 373. doi: 10.3390/ijms17030373.
Soumakis, S. A., Berg, D. and Harris, H. W. (1998) ‘Hypothyroidism in a Patient Receiving Treatment for Multidrug‐Resistant Tuberculosis’, Clinical Infectious Diseases, 27(4), pp. 910–911. doi: 10.1086/517171.
Srivastava, S. et al. (2013) ‘Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?’, The European respiratory journal, 42(6), pp. 1449–53. doi: 10.1183/09031936.00073213.
STOP TB Partnership, Child Health Subgroup, World Health Organisation, Geneva, S. (2010) ‘Rapid advice: Treatment of Tuberculosis in Children’, WHO, p. WHO/HTM/TB/2010.13.
STOP TB Partnership Child Health Subgroup, W. H. O. (2006) ‘Guidance for national tuberculosis programmes on the management of tuberculosis in children. Chapter 2: anti-tuberculosis treatment in children.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 10(11), pp. 1205–11. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17131777 (Accessed: 4 September 2013).
Sturdy, A. et al. (2011) ‘Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.’, The Journal of antimicrobial chemotherapy, 66(8), pp. 1815–20. doi: 10.1093/jac/dkr221.
Sweetman S, M. (ed.) (no date) The Complete Drug Reference, online edition., The Pharmaceutical Press, London. The Pharmaceutical Press, London.
Tang, S. et al. (2015) ‘Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.’, The European respiratory journal, 45(1), pp. 161–70. doi: 10.1183/09031936.00035114.
The Sentinel Project for Pediatric Drug-Resistant Tuberculosis (2015) ‘Management of Multidrug-Resistant Tuberculosis in Children: A Field Guide’, (March). Available at: http://sentinel-project.org/wp-content/uploads/2015/03/Field_Handbook_2nd_Ed_revised-no-logos_03022015.pdf.
Thee, S., Zöllner, E. W., et al. (2011) ‘Abnormal thyroid function tests in children on ethionamide treatment.’, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 15(9), pp. 1191–3, i. doi: 10.5588/ijtld.10.0707.
Thee, S., Seifart, H. I., et al. (2011) ‘Pharmacokinetics of ethionamide in children.’, Antimicrobial agents and chemotherapy, 55(10), pp. 4594–600. doi: 10.1128/AAC.00379-11.
Tiberi, S. et al. (2016) ‘Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience: TABLE 1’, European Respiratory Journal, 47(1), pp. 333–336. doi: 10.1183/13993003.01278-2015.
Treatment of Tuberculosis: Thioacetazone (no date) People’s Friendship University of Russia, Faculty of Medicine. Available at: http://main.rudn.ru/_new/russian/win/tub1/tubeng2012/05_treat/05_1_7_treat_tiacet.htm.
Tucker, H. (2005) Dear Healthcare Professional Letter. Available at: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM164879.pdf.
WHO (2004) Statement on the position of the stop TB department with regard to thioacetazone + isoniazid within context of the who model list of essential medicines., World Health Organisation. Available at: http://archives.who.int/eml/expcom/expcom14/thioacetazone/thioacetazoneisoniazid_STB_statement_annex_4Nov04.pdf.
WHO (2006) ‘Guidance for National Tuberculosis Programmes on the management of tuberculosis in children’, World Health Organisation. Geneva, p. WHO/HTM/ TB/2006.371, WHO/FCH/CAH/2006.7.
WHO (2009) ‘Treatment of Tuberculosis: guidelines 4th edition.’, WHO, p. WHO/HTM/TB/2009.4.
WHO (2011) ‘Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 Update’, World Health Organisation, p. WHO/HTM/TB/2008.402.
WHO (2013) ‘The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance.’, Geneva: World Health Organization. Available at: http://www.ncbi.nlm.nih.gov/books/NBK154134/.
WHO (2014a) Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis., World Health Organisation. Geneva, Switzerland: World Health Organisation. Available at: http://www.who.int/tb/publications/pmdt_companionhandbook/en/.
WHO (2014b) ‘The use of delamanid in the treatment of multidrug-resistant tuberculosis: An interim policy guidance.’, World Health Organisation. Geneva, Switzerland, (WHO/HTM/TB/2014.23). Available at: http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf?ua=1&ua=1.
WHO (2015) Guidelines on the management of latent tuberculosis infection. Geneva, Switzerland. Available at: http://apps.who.int/iris/bitstream/10665/136471/1/9789241548908_eng.pdf?ua=1&ua=1.
WHO (2022a) ‘Use of delamanid in children and adolescents with multidrug-and rifampicin-resistant tuberculosis-Information note WHO recommendations for delamanid in children and adolescents’, 4(6), pp. 1–8.
WHO (2022b) WHO consolidated guidelines on tuberculosis., WHO Press.
World Health Organization (2018) ‘Technical report on the pharmacokinetics and pharmacodynamics (PK/PD) of medicines used in the treatment of drug-resistant tuberculosis.’, p. 63. Available at: http://apps.who.int/bookorders. (Accessed: 26 April 2020).
World Health Organization (2023) ‘Use of bedaquiline in children and adolescents with multidrug-and rifampicin-resistant tuberculosis-Information note BEDAQUILINE’, 4(5), pp. 1–8. Available at: https://www.who.int/publications/i/item/9789240074286.
Xu, H.-B., Jiang, R.-H. and Xiao, H.-P. (2012) ‘Clofazimine in the treatment of multidrug-resistant tuberculosis.’, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 18(11), pp. 1104–10. doi: 10.1111/j.1469-0691.2011.03716.x.
Zhang, X. et al. (2015) ‘Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.’, Journal of thoracic disease, 7(4), pp. 603–15. doi: 10.3978/j.issn.2072-1439.2015.03.10.
Zhu, M. et al. (2001) ‘Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis.’, Pharmacotherapy, 21(9), pp. 1037–45. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11560193 (Accessed: 4 September 2013).
Zhu, M. et al. (2002) ‘Population pharmacokinetics of ethionamide in patients with tuberculosis.’, Tuberculosis (Edinburgh, Scotland), 82(2–3), pp. 91–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12356460 (Accessed: 26 April 2014).